Genesis Therapeutics

Our Pipeline

1

Genesis Oncology

Using GEMS to generate and optimize first- or best-in-class small molecules for difficult biological targets, which offer potential to advance the treatment of difficult cancers.

2

Genesis Immunology

Using GEMS to generate and optimize first-in-class small molecules for well-validated targets, as well as novel immunology targets.

Genesis Partners

Genesis has partnered with multiple industry leaders to amplify the impact of our AI platform for drug discovery. Combining GEMS with the drug development prowess of our partners, we aim to further accelerate impact for patients.

 

Multi-target collaboration Started 2025

In 2025, Genesis partnered with Incyte to leverage GEMS for Incyte-selected targets. Genesis and Incyte will collaborate on two initial targets, and the agreement included a $30 million upfront payment to Genesis.

Multi-target collaboration Started 2024

In 2024, Genesis partnered with Gilead to deploy GEMS against multiple hard-to-drug targets. Genesis received $35 million in upfront payment to collaborate on 3 initial targets.

Genesis Scientists

Deploying GEMS and Powering our Pipeline

Our world-class team of seasoned drug hunters is headquartered in San Diego. Genesis chemists and biologists collaborate closely to deploy GEMS and discover breakthrough medicines across a number of therapeutic areas.